Current studies | UCB
UCB's Global Corporate Website


A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Brief summary

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

Medical Condition

Primary Immune Thrombocytopenia

Min. Age


Max. Age


Who Can Join?



Inclusion criteria

-Study participant must be ≥18 years of age at the time of the Screening Visit -Study participant has a diagnosis of persistent (>3 months duration) or chronic (>12 months duration) primary immune thrombocytopenia (ITP) at the Screening Visit -Study participant has a documented intolerance or insufficient response to two or more appropriate standard of care ITP medications prior to Screening -Study participants must have prior history of a response to a previous ITP therapy -If taking allowed drugs, study participant must be on stable doses during defined time periods prior to Baseline (Day 1) -Study participant has a documented history of low platelet count (<30x10^9/L) prior to Screening -Study participant has a platelet count measurement at Screening and at Baseline (Day 1) with an average of the two <30x10^9/L and no single count may be >35x10^9/L (using local laboratories) -Study participant has a current or history of a peripheral blood smear consistent with ITP -Study participants may be male or female: a. A male participant must agree to use contraception during the Treatment Period and for at least 3 months after the final dose of study treatment and refrain from donating sperm during this period b. A female participant is eligible to participate if she is not pregnant as confirmed by a negative serum pregnancy test or not planning to get pregnant during the participation in the study, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 3 months after the dose of study treatment

Exclusion criteria

-Participant has a history of arterial or venous thromboembolism (eg, stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism) within the 6 months prior to randomization or requires anticoagulant treatment -Study participant has clinically significant bleeding that warrants immediate platelet adjustment (eg, menorrhagia with significant drop in hemoglobin) -Study participant has a known hypersensitivity to any components of the study medication or any other anti-neonatal Fc receptor (FcRn) medications -Study participant has evidence of a secondary cause of immune thrombocytopenia (eg, past medical history of untreated H. pylori infection, leukemia, lymphoma, common variable immunodeficiency, systemic lupus erythematosus, autoimmune thyroid disease or drug induced), participant has a multiple immune cytopenia (eg, Evan’s syndrome) -Study participant has a clinically relevant active infection (eg, sepsis, pneumonia, or abscess) in the opinion of the investigator, or had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of investigational medicinal product (IMP) -Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current/history of nontuberculous mycobacterial infection (NTMBI) -Study participant has a history of a major organ transplant or hematopoietic stem cell/marrow transplant -Study participant has experienced intracranial bleed in the last 6 months prior to the Screening Visit -Study participant has a history of coagulopathy disorders other than ITP -Study participant has a Karnofsky Performance Status rating <60% at the Screening Visit -Study participant with current or medical history of immunoglobulin A (IgA) deficiency, or a measurement of IgA <50 mg/dL at the Screening Visit -Study participant has undergone a splenectomy in the 2 years prior to the Baseline Visit

Study Medication Description

Study Medication:


Other Descriptive Name:






Study Dates

January 2020

Actual Start Date of Enrollment

August 2022

Planned Study Completion Date

General Information

Study ID:
EudraCT Number:
2019-000884-26 Number:
Phase 3

Interested in enrolling in our study?

Just contact us

+43 (0) 1 291 80 08
0800-296176 (freephone)

+32 2 559 92 00
0800 38 008 (freephone)

+359 2 962 9933

Czech Republic
+420 221 773 442
800 144 395 (freephone)

+45 32462480
80 253827 (freephone)

+358 942733300
0800 9 13353 (freephone)

+33 1 47 29 45 55
0 805 222 949 (freephone)

+49 2173 48 48 48

+30 21 0997 4200
0080 012 9910 (freephone)

+36 1 472 5060
06 80 021 486 (freephone)

+353 1 463 2371
1800 93 00 75 (freephone)

+39 02 3007 9300
8009-86932 (freephone)

+32 2 559 92 12
8002 3204 (freephone)

+45 32462482
800-10101 (freephone)

+48 22 596 97 97
00 800 121 68 25 (freephone)

+351 213 025 300
800-8-56033 (freephone)


+4021 300 19 07

+421 2 592 020 23
0800 002 566 (freephone)

+34 915 70 06 49
8000-99684 (freephone)

+45 32462481
0200 898 671 (freephone)


+41 58 822 3180

The Netherlands
+31 76 573 1130
0800 3434335 (freephone)

+44 1753 777 100
0800 279 3177 (freephone)